MGC Pharmaceuticals’ (ASX:MXC) results suggest further applications for CimetrA
MGC Pharmaceuticals (MXC) indicates CimetrA has a wide-ranging application as an anti-inflammatory…
Mgc Pharmaceuticals Ltd (ASX:MXC)
About Mgc Pharmaceuticals Ltd
Key Information
MXC In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 06/07/2022 | Launch of Medical Data Collection App - ZAM | 951.45KB | 422 |
| 27/06/2022 | Price Sensitive PS CimetrA anti-inflammatory pre-clinical study results | 1.11MB | 5.3K |
| 24/06/2022 | US Market Update - CimetrA Clinical Trial Progress | 240.54KB | 600 |
| 16/06/2022 | Price Sensitive PS Glioblastoma pre-clinical trial results | 1.14MB | 2.1K |
| 06/06/2022 | Price Sensitive PS Cognicann Clinical Trial Results | 348.51KB | 3.0K |
| 18/05/2022 | Price Sensitive PS Response to ASX Aware Query | 1.18MB | 2.2K |
| 13/05/2022 | s708A(5)(e) Cleansing Notice | 232.99KB | 278 |
| 13/05/2022 | Application for quotation of securities - MXC | 24.97KB | 1.6K |